Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo

BACKGROUND: The MEK1/2 inhibitor selumetinib was recently approved for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but outcomes could be improved and its pharmacodynamic evaluation in other relevant tissues is limited. The aim of this study was to assess selumetinib tissue pha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Osum, Sara H, Coutts, Alexander W, Duerre, Dylan J, Tschida, Barbara R, Kirstein, Mark N, Fisher, James, Bell, W Robert, Delpuech, Oona, Smith, Paul D, Widemann, Brigitte C, Moertel, Christopher L, Largaespada, David A, Watson, Adrienne L
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095338/
https://ncbi.nlm.nih.gov/pubmed/33978635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdab020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados